Search details
1.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology
; 99(12): 747-755, 2021.
Article
in English
| MEDLINE | ID: mdl-34583356
2.
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Curr Urol Rep
; 20(11): 68, 2019 Oct 11.
Article
in English
| MEDLINE | ID: mdl-31605269
3.
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Anticancer Drugs
; 28(1): 110-115, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27763885
4.
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Eur J Clin Pharmacol
; 73(2): 157-164, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27864592
5.
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Clin Genitourin Cancer
; 22(3): 102078, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38631104
6.
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Clin Genitourin Cancer
; 22(3): 102074, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38616147
7.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37481365
8.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Minerva Urol Nephrol
; 75(4): 460-470, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37530662
9.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Target Oncol
; 18(4): 559-570, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37369815
10.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Clin Genitourin Cancer
; 21(5): e309-e319.e1, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37062658
11.
Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC.
Anticancer Res
; 42(5): 2241-2247, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35489718
12.
Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study.
Tumori
; 108(3): 250-257, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-33818208
13.
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Target Oncol
; 17(5): 571-581, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35947324
14.
A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma.
Cancers (Basel)
; 14(1)2021 Dec 30.
Article
in English
| MEDLINE | ID: mdl-35008342
15.
[Pharmacogenomics and chemotherapy]. / Farmacogenomica e chemioterapia: attuali conoscenze.
Recenti Prog Med
; 101(7-8): 277-82, 2010.
Article
in Italian
| MEDLINE | ID: mdl-20842953
16.
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
Clin Lung Cancer
; 20(3): 178-185.e2, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30910574
17.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
J Cancer Res Clin Oncol
; 145(2): 479-485, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30506406
18.
Castration-resistance prostate cancer: what is in the pipeline?
Minerva Urol Nefrol
; 70(1): 22-41, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-28707844
19.
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Anticancer Res
; 38(7): 3789-3796, 2018 Jul.
Article
in English
| MEDLINE | ID: mdl-29970498
20.
Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
Anticancer Res
; 38(11): 6029-6039, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30396917